Issued Patents 2017
Showing 25 most recent of 31 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 9849176 | RS7 antibodies | Serengulam V. Govindan, Zhengxing Qu, Hans J. Hansen | 2017-12-26 |
| 9839689 | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy | Chien-Hsing Chang | 2017-12-12 |
| 9833511 | RS7 antibodies | Serengulam V. Govindan, Zhengxing Qu, Hans J. Hansen | 2017-12-05 |
| 9809646 | Methods for treating thrombosis using chimeric and humanized anti-histone antibodies | Chien-Hsing Chang, Hans J. Hansen | 2017-11-07 |
| 9797907 | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells | Hans J. Hansen, Chien-Hsing Chang | 2017-10-24 |
| 9770517 | Anti-Trop-2 antibody-drug conjugates and uses thereof | Serengulam V. Govindan | 2017-09-26 |
| 9757458 | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells | Chien-Hsing Chang | 2017-09-12 |
| 9751948 | Class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type I receptor (IGF-1R) | Chien-Hsing Chang, Michele J. Losman | 2017-09-05 |
| 9745374 | Fusion proteins containing recombinant cytotoxic RNAses | Hans J. Hansen, Chien-Hsing Chang, Sailaja S. Vanama, Edmund A. Rossi | 2017-08-29 |
| 9745380 | RS7 antibodies | Serengulam V. Govindan, Zhengxing Qu, Hans J. Hansen | 2017-08-29 |
| 9737617 | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases | Chien-Hsing Chang, Edmund A. Rossi | 2017-08-22 |
| 9707302 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | Thomas M. Cardillo | 2017-07-18 |
| 9707300 | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites | Serengulam V. Govindan, Sung-Ju Moon, Chien-Hsing Chang | 2017-07-18 |
| 9701748 | Humanized anti-CD22 antibody | Chien-Hsing Chang | 2017-07-11 |
| 9700634 | Immunoconjugates with an intracellularly-cleavable linkage | Serengulam V. Govindan, Sung-Ju Moon | 2017-07-11 |
| 9694088 | Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer | Serengulam V. Govindan, William J. McBride, Nalini Sathyanarayan, Christine Mazza-Ferreira | 2017-07-04 |
| 9687547 | T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines | Sofia Stenler, Britta Wahren, Chien-Hsing Chang | 2017-06-27 |
| 9683050 | Stable compositions of high-concentration allotype-selected antibodies for small-volume administration | Li Zeng, Rohini Mitra, Edmund A. Rossi, Hans J. Hansen | 2017-06-20 |
| 9682143 | Combination therapy for inducing immune response to disease | Chien-Hsing Chang, Edmund A. Rossi, Diane Rossi | 2017-06-20 |
| 9675706 | Immunoconjugates with an intracellularly-cleavable linkage | Serengulam V. Govindan, Sung-Ju Moon | 2017-06-13 |
| 9670286 | Disease therapy by inducing immune response to Trop-2 expressing cells | Chien-Hsing Chang, Edmund A. Rossi, Diane Rossi | 2017-06-06 |
| 9663576 | Therapeutic use of anti-CD22 antibodies for inducing trogocytosis | Chien-Hsing Chang, Hans J. Hansen, Edmund A. Rossi | 2017-05-30 |
| 9657093 | Methods for treating sepsis using chimeric and humanized anti-histone antibodies | Chien-Hsing Chang, Hans J. Hansen | 2017-05-23 |
| 9629926 | Antibody-SN-38 immunoconjugates with a CL2A linker | Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman | 2017-04-25 |
| 9623115 | Dock-and-Lock (DNL) Complexes for Disease Therapy | Chien-Hsing Chang | 2017-04-18 |